CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Peng Zhang und 16 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Interferon-alpha, CD8-Positive T-Lymphocytes, Antiviral Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Beijing Nova Program.
Abstract (Originalsprache)
Background & Aims Pegylated interferon‐alpha (PEG‐IFN‐α) is the first choice for achieving functional cure (FC) in chronic hepatitis B (CHB), but only about 30% of patients achieve this outcome within a defined treatment duration. Given the critical role of CD8 + T cells as antiviral effectors, we investigated their changes during FC to identify novel predictive markers of treatment efficacy.
Methods
We enrolled CHB patients with serum HBsAg levels < 3000 IU/mL in a discovery cohort and collected their peripheral blood mononuclear cells after PEG‐IFN‐α therapy. We used single‐cell transcriptome profiling coupled with T cell receptor (TCR) sequencing and flow cytometry to assess CD8 + T cell immune characteristics. Findings were validated longitudinally by flow cytometry in an independent cohort receiving PEG‐IFN‐α therapy.
Results
In FC patients, CD8 + T cell subsets exhibited distinct transcriptional profiles. c04 (Temra/Teff) and c06 (proliferating T) showed significant clonal expansion compared to non‐FC patients. CD300A expression was highly enriched in FC cells, correlating with cytotoxicity‐related gene signatures (e.g., GZMB , GNLY , PRF1 ). CD300A + CD8 + T cells demonstrated greater clonal expansion, enhanced antigen reactivity and a transcriptional network driven by TBX21 and EOMES , with enrichment of HBV‐specific CD8 + T cells. Longitudinal validation confirmed that baseline CD300A + CD8 + T cells, particularly non‐naive subsets, were associated with greater HBsAg decline and earlier FC, independent of baseline HBsAg levels.
Conclusions
CD300A + CD8 + T cells are enriched in patients achieving FC during PEG‐IFN‐α therapy, exhibiting robust clonal expansion, enhanced cytotoxicity and HBV antigen specificity. These cells may serve as potential biomarkers for treatment response to improve FC rates in CHB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
- Senior Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, Peking University 302 Clinical Medical School, National Clinical Research Center for Infectious Diseases, Beijing, Chin…
ORCID-Profile: Fu-Sheng Wang, Chao Zhang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Beijing Nova Program
- capital clinical diagnosis and treatment technology research and transformation application project
Zitieren
APA
Zhang, P., Wang, W. X., Li, J., Lv, Q., Zhu, M. M., Wang, Y. Y., Zhou, M. J., Chen, S. Y., Jiao, Y. M., Fan, X., Song, J. W., Xu, R., Zhen, C., Shi, M., Wang, F. S., Fu, J., & Zhang, C. (2025). CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70214
Vancouver
Zhang P, Wang WX, Li J, Lv Q, Zhu MM, Wang YY, et al. CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70214
BibTeX
@article{Zhang2025,
author = {Zhang, Peng and Wang, Wen-Xin and Li, Jing and Lv, Qiaolan and Zhu, Meng-Meng and Wang, You-Yuan and Zhou, Ming-Ju and Chen, Si-Yuan and Jiao, Yan-Mei and Fan, Xing and Song, Jin-Wen and Xu, Ruonan and Zhen, Cheng and Shi, Ming and Wang, Fu-Sheng and Fu, Junliang and Zhang, Chao},
title = {CD300A + CD8 + T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70214}
}
EUVIMED